No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial | Zendy

Thomas Kjær | Zendy; Marie Juul Ørnstrup | Zendy; Morten Møller Poulsen | Zendy; Hans StødkildeJørgensen | Zendy; Niels Jessen | Zendy; Jens Otto Lunde Jørgensen | Zendy; Bjørn Richelsen | Zendy; Steen B. Pedersen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial

Author(s) -

Thomas Kjær,

Marie Juul Ørnstrup,

Morten Møller Poulsen,

Hans StødkildeJørgensen,

Niels Jessen,

Jens Otto Lunde Jørgensen,

Bjørn Richelsen,

Steen B. Pedersen

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-2160

Subject(s) - medicine , fructosamine , endocrinology , metabolic syndrome , glucose homeostasis , adipose tissue , placebo , c reactive protein , inflammation , insulin resistance , diabetes mellitus , obesity , pathology , alternative medicine

Low-grade inflammation is associated with obesity and the metabolic syndrome (MetS). Preclinical evidence suggests that resveratrol (RSV) has beneficial metabolic and anti-inflammatory effects that could have therapeutic implications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research